Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 5/20 | 0.68 |
| ▸ | RNPEP | Q9H4A4 | 4/20 | 0.68 |
| ▸ | DNPEP | Q9ULA0 | 4/20 | 0.68 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.46 |
| ▸ | LAP3 | P28838 | 3/20 | 0.45 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RRM1 | P23921 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1277891 | 1.00 | ANPEP (0.68) | ANPEPRNPEPDNPEPSLC7A5DPP7 | |
| SCHEMBL14067667 | 1.00 | ANPEP (0.68) | ANPEPRNPEPDNPEPSLC7A5DPP7 | |
| Hydrochloric Acid SCHEMBL1277930 | 0.98 | ANPEP (0.66) | ANPEPRNPEPDNPEPSLC7A5DPP7 | |
| Bromide SCHEMBL7305048 | 0.98 | ANPEP (0.66) | ANPEPRNPEPDNPEPSLC7A5DPP7 | |
| SCHEMBL1769033 | 0.87 | SLC7A5 (0.59) | ANPEPRNPEPDNPEPSLC7A5DPP7 | |
| SCHEMBL1769602 | 0.87 | SLC7A5 (0.59) | ANPEPRNPEPDNPEPSLC7A5DPP7 | |
| SCHEMBL1768387 | 0.87 | SLC7A5 (0.59) | ANPEPRNPEPDNPEPSLC7A5DPP7 | |
| SCHEMBL1769031 | 0.87 | SLC7A5 (0.59) | ANPEPRNPEPDNPEPSLC7A5DPP7 | |
| Bromide SCHEMBL7287179 | 0.86 | ANPEP (0.57) | ANPEPRNPEPDNPEPSLC7A5LAP3 | |
| SCHEMBL9113004 | 0.86 | DPP7 (0.52) | ANPEPRNPEPDNPEPSLC7A5DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398749-A1 | INHALABLE PROTEASE INHIBITORS FOR USE IN THE PREVENTION AND/OR TREATMENT OF FIBROTIC AUTOIMMUNE OR INFLAMMATORY LUNG DISEASES | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2024-12-05 | — | — | US | disclosed |
| US-20230233510-A1 | CYSTEINE PROTEASE INHIBITORS FOR USE IN THE PREVENTION AND/OR TREATMENT OF CORONAVIRUS | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2023-07-27 | — | — | US | disclosed |
| EP-4166136-A1 | INHALABLE PROTEASE INHIBITORS FOR USE IN THE PREVENTION AND/OR TREATMENT OF FIBROTIC AUTOIMMUNE OR INFLAMMATORY LUNG DISEASES | Albert-Ludwigs-Universität Freiburg (DE) | 2023-04-19 | — | — | EP | disclosed |
| EP-4135685-A1 | CYSTEINE PROTEASE INHIBITORS FOR USE IN THE PREVENTION AND/OR TREATMENT OF CORONAVIRUS | Albert-Ludwigs-Universität Freiburg (DE) | 2023-02-22 | — | — | EP | disclosed |
| CN-115666550-A | Cysteine protease inhibitors for the prevention and/or treatment of coronaviruses | 阿尔伯特-路德维希-弗莱堡大学 | 2023-01-31 | — | — | CN | disclosed |
| WO-2021209620-A1 | CYSTEINE PROTEASE INHIBITORS FOR USE IN THE PREVENTION AND/OR TREATMENT OF CORONAVIRUS | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2021-10-21 | — | — | WO | disclosed |
| US-20170166543-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING (2S,3S)-TRANS-EPOXYSUCCINYL-L-LEUCYL-AMIDO-3-METHYLBUTANE ETHYL ESTER | AMERICAN LIFE SCIENCE PHARMACEUTICALS INC (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170166543-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING (2S,3S)-TRANS-EPOXYSUCCINYL-L-LEUCYL-AMIDO-3-METHYLBUTANE ETHYL ESTER | AMERICAN LIFE SCIENCE PHARMACEUTICALS INC (US) | 2017-06-15 | — | — | US | disclosed |
| WO-2015117094-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING (2S,3S)-TRANS-EPOXYSUCCINYL-L-LEUCYL-AMIDO-3-METHYLBUTANE ETHYL ESTER | AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC. (US) | 2015-08-06 | — | — | WO | disclosed |
| US-20120088848-A1 | METHODS AND COMPOSITIONS FOR CONTROLLED POLYPEPTIDE SYNTHESIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2012-04-12 | — | — | US | disclosed |
| US-6686446-B2 | INITIATING THE POLYMERIZATION OF AMINOACID-N-CARBOXYANHYDRIDE (NCA) MONOMER BY COMBINING THE MONOMER WITH AN AMIDO-CONTAINING METALLACYCLE, FOR MAKING SELF ASSEMBLING AMPHIPHILIC BLOCK COPOLYPEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-02-03 | — | — | US | disclosed |
| US-6632922-B1 | Mixing allyloxycarbonyl-amino acid amide and transition metal-Lewis base ligand; complexing, cyclization, metallization | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-10-14 | — | — | US | disclosed |
| EP-1189928-A1 | METHODS AND COMPOSITIONS FOR CONTROLLED POLYPEPTIDE SYNTHESIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2002-03-27 | — | — | EP | disclosed |
| US-20020032309-A1 | Methods and compositions for controlled polypeptide synthesis | NATIONAL SCIENCE FOUNDATION | 2002-03-14 | — | — | US | disclosed |
| WO-2001094379-A2 | METHODS AND COMPOSITIONS FOR CONTROLLED SYNTHESIS OF AMINO ACID POLYMERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2000068252-A1 | METHODS AND COMPOSITIONS FOR CONTROLLED POLYPEPTIDE SYNTHESIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-11-16 | — | — | WO | disclosed |
| US-6114537-A | 1,2,4-THIADIAZOLE COMPOUND IS USEFUL FOR TRAPPING THIOL COMPOUNDS AND SELECTIVELY CHANGING THIOLS TO DISULFIDE COMPOUNDS | APOTEX INC. (CA) | 2000-09-05 | — | — | US | disclosed |
| EP-0883606-A1 | PROCESS FOR SCAVENGING THIOLS | APOTEX INC. (CA) | 1998-12-16 | — | — | EP | disclosed |
| WO-1997031893-A1 | PROCESS FOR SCAVENGING THIOLS | APOTEX INC. (CA) | 1997-09-04 | — | — | WO | disclosed |
| US-5214056-A | Thiol protease inhibitors | JAPAN TOBACCO INC. (JP) | 1993-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088848-A1 | METHODS AND COMPOSITIONS FOR CONTROLLED POLYPEPTIDE SYNTHESIS | NGLY1, LNPEP, NPPA | ANPEP 4/4885RNPEP 16/4885DNPEP 5/4885 |
| US-20230233510-A1 | CYSTEINE PROTEASE INHIBITORS FOR USE IN THE PREVENTION AND/OR TREATMENT OF CORONAVIRUS | ACE, PRSS1, CPA1 | ANPEP 85/4885RNPEP 55/4885DNPEP 68/4885 |
| US-20170166543-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING (2S,3S)-TRANS-EPOXYSUCCINYL-L-LEUCYL-AMIDO-3-METHYLBUTANE ETHYL ESTER | PTMS, LTA, LPXN | ANPEP 21/4885RNPEP 539/4885DNPEP 164/4885 |
| US-20020032309-A1 | Methods and compositions for controlled polypeptide synthesis | NGLY1, LNPEP, NPPA | ANPEP 4/4885RNPEP 16/4885DNPEP 5/4885 |
| US-20240398749-A1 | INHALABLE PROTEASE INHIBITORS FOR USE IN THE PREVENTION AND/OR TREATMENT OF FIBROTIC AUTOIMMUNE OR INFLAMMATORY LUNG DISEASES | MMP1, SERPINB1, SPINT2 | ANPEP 165/4885RNPEP 74/4885DNPEP 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.